REFERENCES
1. Kitching AR, Anders HJ, Basu N, et al. ANCA-associated vasculitis. Nat Rev Dis Primers. 2020;6:71.
2. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised international Chapel Hill consensus conference nomenclature of vasculitides. Arthritis Rheum. 2013;65:1-11.
3. Hellmich B, Sanchez-Alamo B, Schirmer JH, et al. EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis. 2024;83:30-47.
4. Tan JA, Dehghan N, Chen W, Xie H, Esdaile JM, Avina-Zubieta JA. Mortality in ANCA-associated vasculitis: ameta-analysis of observational studies. Ann Rheum Dis. 2017;76:1566-74.
5. Robson J, Doll H, Suppiah R, et al. Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials. Ann Rheum Dis. 2015;74:177-84.
6. Basu N, McClean A, Harper L, et al. The characterisation and determinants of quality of life in ANCA associated vasculitis. Ann Rheum Dis. 2014;73:207-11.
7. Raimundo K, Farr AM, Kim G, Duna G. Clinical and economic burden of antineutrophil cytoplasmic antibody-associated vasculitis in the United States. J Rheumatol. 2015;42:2383-91.
8. Gill N, Tervaert JWC, Yacyshyn E. Vasculitis patient journey: a scoping review of patient experiences with vasculitis. Clin Rheumatol. 2021;40:1697-708.
9. Jones RB, Tervaert JW, Hauser T, et al. European Vasculitis Study Group. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363:211-20.
10. Walsh M, Flossmann O, Berden A, et al. European Vasculitis Study Group. Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2012;64:542-8.
11. Jayne DRW, Merkel PA, Schall TJ, Bekker P. ADVOCATE Study Group. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med. 2021;384:599-609.
12. Hellmich B, Flossmann O, Gross WL, et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis. 2007;66:605-17.
13. Sangle S, Karim MY, Hughes GR, D'Cruz DP. Sulphamethoxazole-trimethoprim in the treatment of limited paranasal Wegener's granulomatosis. Rheumatology. 2002;41:589-90.
14. Tervaert JW. Trimethoprim-sulfamethoxazole and antineutrophil cytoplasmic antibodies-associated vasculitis. Curr Opin Rheumatol. 2018;30:388-94.
15. Monti S, Delvino P, Riboli M, et al. The role of trimethoprim/sulfametoxazole in reducing relapses and risk of infections in ANCA-associated vasculitis: a meta-analysis. Rheumatology. 2021;60:3553-64.
16. Gachelin G, Garner P, Ferroni E, Tröhler U, Chalmers I. Evaluating Cinchona bark and quinine for treating and preventing malaria. J R Soc Med. 2017;110:31-40.
17. Ben-Zvi I, Kivity S, Langevitz P, Shoenfeld Y. Hydroxychloroquine: from malaria to autoimmunity. Clin Rev Allergy Immunol. 2012;42:145-53.
18. Dima A, Jurcut C, Chasset F, Felten R, Arnaud L. Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge. Ther Adv Musculoskelet Dis. 2022;14:1759720X211073001.
19. Goss A. Building the world's supply of quinine: dutch colonialism and the origins of a global pharmaceutical industry. Endeavour. 2014;38:8-18.
20. Payne JF. A postgraduate lecture on lupus erythematosus. J Clin Med. 1894;4:223-9.
23. Lewis HM, Frumess GM. Plaquenil in the treatment of discoid lupus erythematosus; a preliminary report. AMA Arch Derm. 1956;73:576-81.
24. Mullins JF, Watts FL, Wilson CJ. Plaquenil in the treatment of lupus erythematosus. J Am Med Assoc. 1956;161:879-81.
25. Manohar S, Tripathi M, Rawat DS. 4-aminoquinoline based molecular hybrids as antimalarials: an overview. Curr Top Med Chem. 2014;14:1706-33.
26. Rainsford KD, Parke AL, Clifford-Rashotte M, Kean WF. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology. 2015;23:231-69.
27. Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020;16:155-66.
28. Tett SE, Cutler DJ, Day RO, Brown KF. Bioavailability of hydroxychloroquine tablets in healthy volunteers. Br J Clin Pharmacol. 1989;27:771-9.
29. Costedoat-Chalumeau N, Amoura Z, Huong DL, Lechat P, Piette JC. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature. Autoimmun Rev. 2005;4:111-5.
30. Russell MD, Dey M, Flint J, et al. BSR Standards; Audit and Guidelines Working Group. British society for rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids. Rheumatology. 2023;62:e48-88.
31. Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78:736-45.
32. Gordon C, Amissah-Arthur MB, Gayed M, et al. British Society for Rheumatology Standards; Audit and Guidelines Working Group. The British society for rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology. 2018;57:e1-45.
33. Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology. American college of rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res. 2012;64:797-808.
34. Pons-Estel BA, Bonfa E, Soriano ER, et al. Grupo Latino Americano de Estudio del Lupus (GLADEL) and Pan-American League of Associations of Rheumatology (PANLAR). First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American group for the study of lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American league of associations of rheumatology (PANLAR). Ann Rheum Dis. 2018;77:1549-57.
35. Willis R, Seif AM, McGwin G Jr, et al. Effect of hydroxychloroquine treatment on pro-inflammatory cytokines and disease activity in SLE patients: data from LUMINA (LXXV), a multiethnic US cohort. Lupus. 2012;21:830-5.
36. Alarcón GS, McGwin G, Bertoli AM, et al. LUMINA Study Group. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis. 2007;66:1168-72.
37. Costedoat-Chalumeau N, Galicier L, Aumaître O, et al. Group PLUS. Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study). Ann Rheum Dis. 2013;72:1786-92.
38. Miyagawa I, Nakano K, Nakayamada S, et al. The additive effects of hydroxychloroquine to maintenance therapy with standard of care in patients with systemic lupus erythematosus. Int J Rheum Dis. 2020;23:549-58.
39. Petri M, Purvey S, Fang H, Magder LS. Predictors of organ damage in systemic lupus erythematosus: the Hopkins lupus cohort. Arthritis Rheum. 2012;64:4021-8.
40. Pons-Estel GJ, Alarcón GS, González LA, et al. Lumina Study Group. Possible protective effect of hydroxychloroquine on delaying the occurrence of integument damage in lupus: LXXI, data from a multiethnic cohort. Arthritis Care Res. 2010;62:393-400.
41. Rosa GPD, Ortega MF, Teixeira A, Espinosa G, Cervera R. Causes and factors related to hospitalizations in patients with systemic lupus erythematosus: analysis of a 20-year period (1995-2015) from a single referral centre in Catalonia. Lupus. 2019;28:1158-66.
42. Petri M. Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients. Curr Rheumatol Rep. 2011;13:77-80.
43. Ruiz-Irastorza G, Egurbide MV, Pijoan JI, et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus. 2006;15:577-83.
44. Lakshminarayanan S, Walsh S, Mohanraj M, Rothfield N. Factors associated with low bone mineral density in female patients with systemic lupus erythematosus. J Rheumatol. 2001;28:102-8.
45. Calvo-Alén J, McGwin G, Toloza S, et al. LUMINA Study Group. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIV. Cytotoxic treatment is an additional risk factor for the development of symptomatic osteonecrosis in lupus patients: results of a nested matched case-control study. Ann Rheum Dis. 2006;65:785-90.
46. Li XB, Cao NW, Chu XJ, et al. Antimalarials may reduce cancer risk in patients with systemic lupus erythematosus: a systematic review and meta-analysis of prospective studies. Ann Med. 2021;53:1687-95.
47. James JA, Kim-Howard XR, Bruner BF, et al. Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. Lupus. 2007;16:401-9.
48. Pons-Estel GJ, Alarcón GS, Hachuel L, et al. GLADEL. Anti-malarials exert a protective effect while Mestizo patients are at increased risk of developing SLE renal disease: data from a Latin-American cohort. Rheumatology. 2012;51:1293-8.
49. Yokogawa N, Eto H, Tanikawa A, et al. Effects of hydroxychloroquine in patients with cutaneous lupus erythematosus: a multicenter, double-blind, randomized, parallel-group trial. Arthritis Rheumatol. 2017;69:791-9.
50. Chasset F, Arnaud L, Costedoat-Chalumeau N, Zahr N, Bessis D, Francès C. The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): an open-label prospective pilot study. J Am Acad Dermatol. 2016;74:693-9.e3.
51. Chung HS, Hann SK. Lupus panniculitis treated by a combination therapy of hydroxychloroquine and quinacrine. J Dermatol. 1997;24:569-72.
52. Pons-Estel GJ, Alarcón GS, McGwin G Jr, et al. Lumina Study Group. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum. 2009;61:830-9.
53. Lee JS, Oh JS, Kim YG, Lee CK, Yoo B, Hong S. Recovery of renal function in patients with lupus nephritis and reduced renal function: the beneficial effect of hydroxychloroquine. Lupus. 2020;29:52-7.
54. Clowse ME, Magder L, Witter F, Petri M. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum. 2006;54:3640-7.
55. Cortés-Hernández J, Ordi-Ros J, Paredes F, Casellas M, Castillo F, Vilardell-Tarres M. Clinical predictors of fetal and maternal outcome in systemic lupus erythematosus: a prospective study of 103 pregnancies. Rheumatology. 2002;41:643-50.
56. Koh JH, Ko HS, Kwok SK, Ju JH, Park SH. Hydroxychloroquine and pregnancy on lupus flares in Korean patients with systemic lupus erythematosus. Lupus. 2015;24:210-7.
57. Saavedra MÁ, Miranda-Hernández D, Lara-Mejía A, et al. Use of antimalarial drugs is associated with a lower risk of preeclampsia in lupus pregnancy: a prospective cohort study. Int J Rheum Dis. 2020;23:633-40.
58. Seo MR, Chae J, Kim YM, et al. Hydroxychloroquine treatment during pregnancy in lupus patients is associated with lower risk of preeclampsia. Lupus. 2019;28:722-30.
59. Balevic SJ, Cohen-Wolkowiez M, Eudy AM, Green TP, Schanberg LE, Clowse MEB. Hydroxychloroquine levels throughout pregnancies complicated by rheumatic disease: implications for maternal and neonatal outcomes. J Rheumatol. 2019;46:57-63.
60. Izmirly PM, Costedoat-Chalumeau N, Pisoni CN, et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation. 2012;126:76-82.
61. Rheumatoid arthritis in adults: management. NICE guidelines. Available from: https://www.nice.org.uk/guidance/ng100 [Last accessed on 27 Feb 2024].
62. Smolen JS, Landewé RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82:3-18.
63. Fraenkel L, Bathon JM, England BR, et al. 2021 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2021;73:1108-23.
64. Schapink L, van den Ende CHM, Gevers LAHA, van Ede AE, den Broeder AA. The effects of methotrexate and hydroxychloroquine combination therapy vs methotrexate monotherapy in early rheumatoid arthritis patients. Rheumatology. 2019;58:131-4.
65. Klarenbeek NB, Güler-Yüksel M, van der Kooij SM, et al. The impact of four dynamic, goal-steered treatment strategies on the 5-year outcomes of rheumatoid arthritis patients in the BeSt study. Ann Rheum Dis. 2011;70:1039-46.
66. Carmichael SJ, Beal J, Day RO, Tett SE. Combination therapy with methotrexate and hydroxychloroquine for rheumatoid arthritis increases exposure to methotrexate. J Rheumatol. 2002;29:2077-83.
67. Rempenault C, Combe B, Barnetche T, et al. Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2018;77:98-103.
68. Nazir AM, Koganti B, Gupta K, et al. Evaluating the use of hydroxychloroquine in treating patients with rheumatoid arthritis. Cureus. 2021;13:e19308.
69. Makol A, Crowson CS, Wetter DA, Sokumbi O, Matteson EL, Warrington KJ. Vasculitis associated with rheumatoid arthritis: a case-control study. Rheumatology. 2014;53:890-9.
70. Makol A, Matteson EL, Warrington KJ. Rheumatoid vasculitis: an update. Curr Opin Rheumatol. 2015;27:63-70.
71. Wu CL, Chang CC, Kor CT, et al. Hydroxychloroquine use and risk of CKD in patients with rheumatoid arthritis. Clin J Am Soc Nephrol. 2018;13:702-9.
72. Casian A, Sangle SR, D'Cruz DP. New use for an old treatment: hydroxychloroquine as a potential treatment for systemic vasculitis. Autoimmun Rev. 2018;17:660-4.
73. Fox R. Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development. Lupus. 1996;5 Suppl 1:S4-10.
74. So A, Ives A, Joosten LAB, Busso N. Targeting inflammasomes in rheumatic diseases. Nat Rev Rheumatol. 2013;9:391-9.
75. Hamzaoui K, Hamzaoui A. Vasculitis and the NLRP3 inflammasome. Curr Opin Rheumatol. 2024;36:9-15.
76. Tashiro M, Sasatomi Y, Watanabe R, et al. IL-1β promotes tubulointerstitial injury in MPO-ANCA-associated glomerulonephritis. Clin Nephrol. 2016;86:190-9.
77. Wang LY, Sun XJ, Chen M, Zhao MH. The expression of NOD2, NLRP3 and NLRC5 and renal injury in anti-neutrophil cytoplasmic antibody-associated vasculitis. J Transl Med. 2019;17:197.
78. Fujita Y, Matsuoka N, Temmoku J, et al. Hydroxychloroquine inhibits IL-1β production from amyloid-stimulated human neutrophils. Arthritis Res Ther. 2019;21:250.
79. Lucchesi A, Silimbani P, Musuraca G, et al. Clinical and biological data on the use of hydroxychloroquine against SARS-CoV-2 could support the role of the NLRP3 inflammasome in the pathogenesis of respiratory disease. J Med Virol. 2021;93:124-6.
80. Smulski CR, Eibel H. BAFF and BAFF-receptor in B cell selection and survival. Front Immunol. 2018;9:2285.
81. Krumbholz M, Specks U, Wick M, Kalled SL, Jenne D, Meinl E. BAFF is elevated in serum of patients with Wegener's granulomatosis. J Autoimmun. 2005;25:298-302.
82. Nagai M, Hirayama K, Ebihara I, Shimohata H, Kobayashi M, Koyama A. Serum levels of BAFF and APRIL in myeloperoxidase anti-neutrophil cytoplasmic autoantibody-associated renal vasculitis: association with disease activity. Nephron Clin Pract. 2011;118:c339-45.
83. Mumcu G, Biçakçigil M, Yilmaz N, et al. Salivary and serum B-cell activating factor (BAFF) levels after hydroxychloroquine treatment in primary Sjögren's syndrome. Oral Health Prev Dent. 2013;11:229-34.
84. Lambers WM, Westra J, Bootsma H, de Leeuw K. Hydroxychloroquine suppresses interferon-inducible genes and B cell activating factor in patients with incomplete and new-onset systemic lupus erythematosus. J Rheumatol. 2021;48:847-51.
85. Mahdy AA, Raafat HA, El-fishawy HS, Gheita TA. Therapeutic potential of hydroxychloroquine on serum B-cell activating factor belonging to the tumor necrosis factor family (BAFF) in rheumatoid arthritis patients. Bull Fac Pharm Cairo Univ. 2014;52:37-43.
86. Lepse N, Land J, Rutgers A, et al. Toll-like receptor 9 activation enhances B cell activating factor and interleukin-21 induced anti-proteinase 3 autoantibody production in vitro. Rheumatology. 2016;55:162-72.
87. O'Sullivan KM, Ford SL, Longano A, Kitching AR, Holdsworth SR. Intrarenal Toll-like receptor 4 and Toll-like receptor 2 expression correlates with injury in antineutrophil cytoplasmic antibody-associated vasculitis. Am J Physiol Renal Physiol. 2018;315:F1283-94.
88. Wang H, Gou SJ, Zhao MH, Chen M. The expression of Toll-like receptors 2, 4 and 9 in kidneys of patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Clin Exp Immunol. 2014;177:603-10.
89. Holle JU, Windmöller M, Lange C, Gross WL, Herlyn K, Csernok E. Toll-like receptor TLR2 and TLR9 ligation triggers neutrophil activation in granulomatosis with polyangiitis. Rheumatology. 2013;52:1183-9.
90. Tadema H, Abdulahad WH, Lepse N, Stegeman CA, Kallenberg CG, Heeringa P. Bacterial DNA motifs trigger ANCA production in ANCA-associated vasculitis in remission. Rheumatology. 2011;50:689-96.
91. Hurtado PR, Jeffs L, Nitschke J, et al. CpG oligodeoxynucleotide stimulates production of anti-neutrophil cytoplasmic antibodies in ANCA associated vasculitis. BMC Immunol. 2008;9:34.
92. Konstantinov KN, Ulff-Møller CJ, Tzamaloukas AH. Infections and antineutrophil cytoplasmic antibodies: triggering mechanisms. Autoimmun Rev. 2015;14:201-3.
93. Husmann CA, Holle JU, Moosig F, et al. Genetics of toll like receptor 9 in ANCA associated vasculitides. Ann Rheum Dis. 2014;73:890-6.
94. Torigoe M, Sakata K, Ishii A, Iwata S, Nakayamada S, Tanaka Y. Hydroxychloroquine efficiently suppresses inflammatory responses of human class-switched memory B cells via Toll-like receptor 9 inhibition. Clin Immunol. 2018;195:1-7.
95. Cenac C, Ducatez MF, Guéry JC. Hydroxychloroquine inhibits proteolytic processing of endogenous TLR7 protein in human primary plasmacytoid dendritic cells. Eur J Immunol. 2022;52:54-61.
96. Hennessy EJ, Parker AE, O'Neill LA. Targeting Toll-like receptors: emerging therapeutics? Nat Rev Drug Discov. 2010;9:293-307.
97. Gao W, Xiong Y, Li Q, Yang H. Inhibition of Toll-like receptor signaling as a promising therapy for inflammatory diseases: a journey from molecular to nano therapeutics. Front Physiol. 2017;8:508.
98. Hoffmann JC, Patschan D, Dihazi H, et al. Cytokine profiling in anti neutrophil cytoplasmic antibody-associated vasculitis: a cross-sectional cohort study. Rheumatol Int. 2019;39:1907-17.
99. van den Borne BE, Dijkmans BA, de Rooij HH, le Cessie S, Verweij CL. Chloroquine and hydroxychloroquine equally affect tumor necrosis factor-alpha, interleukin 6, and interferon-gamma production by peripheral blood mononuclear cells. J Rheumatol. 1997;24:55-60.
100. Wakiya R, Ueeda K, Nakashima S, et al. Effect of add-on hydroxychloroquine therapy on serum proinflammatory cytokine levels in patients with systemic lupus erythematosus. Sci Rep. 2022;12:10175.
101. Abdulahad WH, Lamprecht P, Kallenberg CG. T-helper cells as new players in ANCA-associated vasculitides. Arthritis Res Ther. 2011;13:236.
102. Abdulahad WH, van der Geld YM, Stegeman CA, Kallenberg CG. Persistent expansion of CD4+ effector memory T cells in Wegener's granulomatosis. Kidney Int. 2006;70:938-47.
103. Valenzuela L, Bordignon Draibe J, Fulladosa Oliveras X, Bestard Matamoros O, Cruzado Garrit JM, Torras Ambrós J. T-lymphocyte in ANCA-associated vasculitis: what do we know? A pathophysiological and therapeutic approach. Clin Kidney J. 2019;12:503-11.
104. Hirayama K, Ishizu T, Shimohata H, et al. Analysis of T-cell receptor usage in myeloperoxidase - antineutrophil cytoplasmic antibody-associated renal vasculitis. Clin Exp Nephrol. 2010;14:36-42.
105. McKinney EF, Lee JC, Jayne DR, Lyons PA, Smith KG. T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection. Nature. 2015;523:612-6.
106. Abdulahad WH, Stegeman CA, van der Geld YM, Doornbos-van der Meer B, Limburg PC, Kallenberg CG. Functional defect of circulating regulatory CD4+ T cells in patients with Wegener's granulomatosis in remission. Arthritis Rheum. 2007;56:2080-91.
107. Kim S, Boehme L, Nel L, et al. Defective STAT5 activation and aberrant expression of BCL6 in naive CD4 T cells enhances follicular Th cell-like differentiation in patients with granulomatosis with polyangiitis. J Immunol. 2022;208:807-18.
108. Goldman FD, Gilman AL, Hollenback C, Kato RM, Premack BA, Rawlings DJ. Hydroxychloroquine inhibits calcium signals in T cells: a new mechanism to explain its immunomodulatory properties. Blood. 2000;95:3460-6.
109. van Loosdregt J, Spreafico R, Rossetti M, Prakken BJ, Lotz M, Albani S. Hydroxychloroquine preferentially induces apoptosis of CD45RO+ effector T cells by inhibiting autophagy: a possible mechanism for therapeutic modulation of T cells. J Allergy Clin Immunol. 2013;131:1443-6.e1.
110. Kowatsch MM, Lajoie J, Mwangi L, et al. Hydroxychloroquine reduces T cells activation recall antigen responses. PLoS One. 2023;18:e0287738.
111. Kim ML, Hardy MY, Edgington-Mitchell LE, et al. Hydroxychloroquine inhibits the mitochondrial antioxidant system in activated T cells. iScience. 2021;24:103509.
112. Taverna S, Tonacci A, Ferraro M, et al. High mobility group box 1: biological functions and relevance in oxidative stress related chronic diseases. Cells. 2022;11:849.
113. Guan H, Zhong M, Ma K, et al. The comprehensive role of high mobility group box 1 (HMGB1) protein in different tumors: a pan-cancer analysis. J Inflamm Res. 2023;16:617-37.
114. Kianian F, Kadkhodaee M, Sadeghipour HR, Karimian SM, Seifi B. An overview of high-mobility group box 1, a potent pro-inflammatory cytokine in asthma. J Basic Clin Physiol Pharmacol. 2020:31.
115. Mo J, Hu J, Cheng X. The role of high mobility group box 1 in neuroinflammatory related diseases. Biomed Pharmacother. 2023;161:114541.
116. Ge Y, Huang M, Yao YM. The Effect and regulatory mechanism of high mobility group box-1 protein on immune cells in inflammatory diseases. Cells. 2021;10:1044.
117. Gou X, Ying J, Yue Y, et al. The roles of high mobility group box 1 in cerebral ischemic injury. Front Cell Neurosci. 2020;14:600280.
118. Vijayakumar EC, Bhatt LK, Prabhavalkar KS. High mobility group box-1 (HMGB1): a potential target in therapeutics. Curr Drug Targets. 2019;20:1474-85.
119. Bruchfeld A, Wendt M, Bratt J, et al. High-mobility group box-1 protein (HMGB1) is increased in antineutrophilic cytoplasmatic antibody (ANCA)-associated vasculitis with renal manifestations. Mol Med. 2011;17:29-35.
120. Wang C, de Souza AW, Westra J, et al. Emerging role of high mobility group box 1 in ANCA-associated vasculitis. Autoimmun Rev. 2015;14:1057-65.
121. Wang C, Gou SJ, Chang DY, Yu F, Zhao MH, Chen M. Association of circulating level of high mobility group box 1 with disease activity in antineutrophil cytoplasmic autoantibody-associated vasculitis. Arthritis Care Res. 2013;65:1828-34.
122. Wibisono D, Csernok E, Lamprecht P, Holle JU, Gross WL, Moosig F. Serum HMGB1 levels are increased in active Wegener's granulomatosis and differentiate between active forms of ANCA-associated vasculitis. Ann Rheum Dis. 2010;69:1888-9.
123. de Souza AW, Westra J, Limburg PC, Bijl M, Kallenberg CG. HMGB1 in vascular diseases: Its role in vascular inflammation and atherosclerosis. Autoimmun Rev. 2012;11:909-17.
124. Niemann B, Puleo A, Stout C, Markel J, Boone BA. Biologic functions of hydroxychloroquine in disease: from COVID-19 to Cancer. Pharmaceutics. 2022;14:2551.
125. Yang M, Cao L, Xie M, et al. Chloroquine inhibits HMGB1 inflammatory signaling and protects mice from lethal sepsis. Biochem Pharmacol. 2013;86:410-8.
126. Laronha H, Caldeira J. Structure and function of human matrix metalloproteinases. Cells. 2020;9:1076.
127. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006;69:562-73.
128. Cabral-Pacheco GA, Garza-Veloz I, Castruita-De la Rosa C, et al. The roles of matrix metalloproteinases and their inhibitors in human diseases. Int J Mol Sci. 2020;21:9739.
129. Zakiyanov O, Chocová Z, Hrušková Z, et al. Matrix metalloproteinases and their tissue inhibitors: an evaluation of novel biomarkers in ANCA-associated vasculitis. Fol Biol. 2019;65:227-36.
130. Sanders JS, Huitema MG, Hanemaaijer R, van Goor H, Kallenberg CG, Stegeman CA. Urinary matrix metalloproteinases reflect renal damage in anti-neutrophil cytoplasm autoantibody-associated vasculitis. Am J Physiol Renal Physiol. 2007;293:F1927-34.
131. Ishizaki J, Takemori A, Horie K, et al. Research Committee of Intractable Vasculitis Syndrome and the Research Committee of Intractable Renal Disease of the Ministry of Health; Labour and Welfare of Japan. Usefulness of tissue inhibitor of metalloproteinase 1 as a predictor of sustained remission in patients with antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Res Ther. 2021;23:91.
132. Rymarz A, Mosakowska M, Niemczyk S. The significance of metalloproteinase 3 (MMP-3), chemokine CXC ligand 13 (CXCL-13) and complement component C5a in different stages of ANCA associated vasculitis. Sci Rep. 2021;11:5132.
133. Lesiak A, Narbutt J, Sysa-Jedrzejowska A, Lukamowicz J, McCauliffe DP, Wózniacka A. Effect of chloroquine phosphate treatment on serum MMP-9 and TIMP-1 levels in patients with systemic lupus erythematosus. Lupus. 2010;19:683-8.
134. Ertugrul G, Keles D, Oktay G, Aktan S. Matrix metalloproteinase-2 and -9 activity levels increase in cutaneous lupus erythematosus lesions and correlate with disease severity. Arch Dermatol Res. 2018;310:173-9.
135. Merkel PA, Lo GH, Holbrook JT, et al. Wegener's Granulomatosis Etanercept Trial Research Group. Brief communication: high incidence of venous thrombotic events among patients with Wegener granulomatosis: the Wegener's clinical occurrence of thrombosis (WeCLOT) study. Ann Intern Med. 2005;142:620-6.
136. Liapi M, Jayne D, Merkel PA, Segelmark M, Mohammad AJ. Venous thromboembolism in ANCA-associated vasculitis: a population-based cohort study. Rheumatology. 2021;60:4616-23.
137. Hilhorst M, Winckers K, Wilde B, van Oerle R, ten Cate H, Tervaert JW. Patients with antineutrophil cytoplasmic antibodies associated vasculitis in remission are hypercoagulable. J Rheumatol. 2013;40:2042-6.
138. Hansrivijit P, Trongtorsak A, Gadhiya KP, et al. Incidence and risk factors of venous thromboembolism in ANCA-associated vasculitis: a metaanalysis and metaregression. Clin Rheumatol. 2021;40:2843-53.
139. Isaacs B, Gapud EJ, Antiochos B, Seo P, Geetha D. Venous thrombotic events in ANCA-Associated vasculitis: incidence and risk factors. Kidney360. 2020;1:258-62.
140. Carter AE, Eban R, Perrett RD. Prevention of postoperative deep venous thrombosis and pulmonary embolism. Br Med J. 1971;1:312-4.
141. Hansen E, Jessing P, Lindewald H, Ostergaard P, Olesen T, Malver E. Hydroxychloroquine sulphate in prevention of deep venous thrombosis following fracture of the hip, pelvis, or thoracolumbar spine. J Bone Joint Surg Am. 1976;58:1089-93.
142. Mekinian A, Lazzaroni MG, Kuzenko A, et al. SNFMI and the European Forum on Antiphospholipid Antibodies. The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: data from a European multicenter retrospective study. Autoimmun Rev. 2015;14:498-502.
143. Belizna C. Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome. Autoimmun Rev. 2015;14:358-62.
144. Espinola R, Pierangeli S, Ghara A, Harris E. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost. 2002;87:518-22.
145. Belizna CC, Richard V, Thuillez C, Lévesque H, Shoenfeld Y. Insights into atherosclerosis therapy in antiphospholipid syndrome. Autoimmun Rev. 2007;7:46-51.
146. Nuri E, Taraborelli M, Andreoli L, et al. Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome. Immunol Res. 2017;65:17-24.
147. Erkan D, Yazici Y, Peterson MG, Sammaritano L, Lockshin MD. A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology. 2002;41:924-9.
148. Rand JH, Wu XX, Quinn AS, et al. Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug. Blood. 2010;115:2292-9.
149. Wu XX, Guller S, Rand JH. Hydroxychloroquine reduces binding of antiphospholipid antibodies to syncytiotrophoblasts and restores annexin A5 expression. Am J Obstet Gynecol. 2011;205:576.e7-14.
150. Bengtsson C, Andersson SE, Edvinsson L, Edvinsson ML, Sturfelt G, Nived O. Effect of medication on microvascular vasodilatation in patients with systemic lupus erythematosus. Basic Clin Pharmacol Toxicol. 2010;107:919-24.
151. Tanay A, Leibovitz E, Frayman A, Zimlichman R, Shargorodsky M, Gavish D. Vascular elasticity of systemic lupus erythematosus patients is associated with steroids and hydroxychloroquine treatment. Ann N Y Acad Sci. 2007;1108:24-34.
152. Folci M, Ramponi G, Shiffer D, Zumbo A, Agosti M, Brunetta E. ANCA-Associated vasculitides and hematologic malignancies: lessons from the past and future perspectives. J Immunol Res. 2019;2019:1732175.
153. Heijl C, Harper L, Flossmann O, et al. European Vasculitis Study Group (EUVAS). Incidence of malignancy in patients treated for antineutrophil cytoplasm antibody-associated vasculitis: follow-up data from European vasculitis study group clinical trials. Ann Rheum Dis. 2011;70:1415-21.
154. Mahr A, Heijl C, Le Guenno G, Faurschou M. ANCA-associated vasculitis and malignancy: current evidence for cause and consequence relationships. Best Pract Res Clin Rheumatol. 2013;27:45-56.
155. van Daalen EE, Rizzo R, Kronbichler A, et al. Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis. Ann Rheum Dis. 2017;76:1064-9.
156. Geser A, Brubaker G, Draper CC. Effect of a malaria suppression program on the incidence of African Burkitt's lymphoma. Am J Epidemiol. 1989;129:740-52.
157. Gheitasi H, Kostov B, Solans R, et al. SS Study Group; Autoimmune Diseases Study Group (GEAS); Spanish Society of Internal Medicine (SEMI). How are we treating our systemic patients with primary Sjögren syndrome? Analysis of 1120 patients. Int Immunopharmacol. 2015;27:194-9.
158. Ko KM, Moon SJ. Prevalence, incidence, and risk factors of malignancy in patients with rheumatoid arthritis: a nationwide cohort study from Korea. Korean J Intern Med. 2023;38:113-24.
159. Lee H, Chen SK, Gautam N, et al. Risk of malignant melanoma and non-melanoma skin cancer in rheumatoid arthritis patients initiating methotrexate versus hydroxychloroquine: a cohort study. Clin Exp Rheumatol. 2023;41:110-7.
160. Houben E, Penne EL, Voskuyl AE, et al. Cardiovascular events in anti-neutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis of observational studies. Rheumatology. 2018;57:555-62.
161. Massicotte-Azarniouch D, Petrcich W, Walsh M, et al. Association of anti-neutrophil cytoplasmic antibody-associated vasculitis and cardiovascular events: a population-based cohort study. Clin Kidney J. 2022;15:681-92.
162. Raza K, Thambyrajah J, Townend JN, et al. Suppression of inflammation in primary systemic vasculitis restores vascular endothelial function: lessons for atherosclerotic disease? Circulation. 2000;102:1470-2.
163. Booth AD, Jayne DR, Kharbanda RK, et al. Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation. Circulation. 2004;109:1718-23.
164. Clifford AH, Cohen Tervaert JW. Cardiovascular events and the role of accelerated atherosclerosis in systemic vasculitis. Atherosclerosis. 2021;325:8-15.
165. Tervaert JW. Cardiovascular disease due to accelerated atherosclerosis in systemic vasculitides. Best Pract Res Clin Rheumatol. 2013;27:33-44.
166. Penn SK, Kao AH, Schott LL, et al. Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol. 2010;37:1136-42.
167. Petri M. Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus. 1996;5:16-22.
168. Solomon DH, Garg R, Lu B, et al. Effect of hydroxychloroquine on insulin sensitivity and lipid parameters in rheumatoid arthritis patients without diabetes mellitus: a randomized, blinded crossover trial. Arthritis Care Res. 2014;66:1246-51.
169. Petri M, Lakatta C, Magder L, Goldman D. Effect of prednisone and hydroxychloroquine on coronary artery disease risk factors in systemic lupus erythematosus: a longitudinal data analysis. Am J Med. 1994;96:254-9.
170. Xu T, Chen Z, Jiang M, et al. Association between different infection profiles and one-year outcomes in ANCA-associated vasculitis: a retrospective study with monthly infection screening. RMD Open. 2022;8:e002424.
171. Flossmann O, Berden A, de Groot K, et al. European Vasculitis Study Group. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis. 2011;70:488-94.
172. Ruiz-Irastorza G, Olivares N, Ruiz-Arruza I, Martinez-Berriotxoa A, Egurbide MV, Aguirre C. Predictors of major infections in systemic lupus erythematosus. Arthritis Res Ther. 2009;11:R109.
173. Smitten AL, Choi HK, Hochberg MC, et al. The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol. 2008;35:387-93.
174. Yusuf IH, Foot B, Lotery AJ. The royal college of ophthalmologists recommendations on monitoring for hydroxychloroquine and chloroquine users in the United Kingdom (2020 revision): executive summary. Eye. 2021;35:1532-7.
175. Learoyd AE, Arnold L, Reid F, et al. HAVEN study group. The HAVEN study-hydroxychloroquine in ANCA vasculitis evaluation-a multicentre, randomised, double-blind, placebo-controlled trial: study protocol and statistical analysis plan. Trials. 2023;24:261.
176. Price EJ, Rauz S, Tappuni AR, et al. British Society for Rheumatology Standards; Guideline and Audit Working Group. The British society for rheumatology guideline for the management of adults with primary Sjögren's syndrome. Rheumatology. 2017;56:e24-48.
177. Ramos-Casals M, Brito-Zerón P, Bombardieri S, et al. EULAR-Sjögren Syndrome Task Force Group. EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies. Ann Rheum Dis. 2020;79:3-18.
178. Fox R, Dixon R, Guarrasi V, Krubel S. Treatment of primary Sjögren's syndrome with hydroxychloroquine: a retrospective, open-label study. Lupus. 1996;5:31-6.
179. Cankaya H, Alpöz E, Karabulut G, Güneri P, Boyacioglu H, Kabasakal Y. Effects of hydroxychloroquine on salivary flow rates and oral complaints of Sjögren patients: a prospective sample study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;110:62-7.
180. Kruize AA, Hené RJ, Kallenberg CG, et al. Hydroxychloroquine treatment for primary Sjögren's syndrome: a two year double blind crossover trial. Ann Rheum Dis. 1993;52:360-4.
181. Fox RI, Chan E, Benton L, Fong S, Friedlaender M, Howell FV. Treatment of primary Sjögren's syndrome with hydroxychloroquine. Am J Med. 1988;85:62-7.
182. Yoon CH, Lee HJ, Lee EY, et al. Effect of hydroxychloroquine treatment on dry eyes in subjects with primary sjögren's syndrome: a double-blind randomized control study. J Korean Med Sci. 2016;31:1127-35.
183. Gottenberg JE, Ravaud P, Puéchal X, et al. Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial. JAMA. 2014;312:249-58.
184. Wang SQ, Zhang LW, Wei P, Hua H. Is hydroxychloroquine effective in treating primary Sjogren's syndrome: a systematic review and meta-analysis. BMC Musculoskelet Disord. 2017;18:186.
185. Tektonidou MG, Andreoli L, Limper M, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;78:1296-304.
186. Erkan D, Unlu O, Sciascia S, et al. APS ACTION. Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease. Lupus. 2018;27:399-406.
187. Sciascia S, Hunt BJ, Talavera-Garcia E, Lliso G, Khamashta MA, Cuadrado MJ. The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies. Am J Obstet Gynecol. 2016;214:273.e1-8.
188. Hooper A, Bacal V, Bedaiwy MA. Does adding hydroxychloroquine to empiric treatment improve the live birth rate in refractory obstetrical antiphospholipid syndrome? A systematic review. Am J Reprod Immunol. 2023;90:e13761.
189. Edwards MH, Pierangeli S, Liu X, Barker JH, Anderson G, Harris EN. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation. 1997;96:4380-4.
190. Baughman RP, Valeyre D, Korsten P, et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J. 2021;58:2004079.
191. Thillai M, Atkins CP, Crawshaw A, et al. BTS clinical statement on pulmonary sarcoidosis. Thorax. 2021;76:4-20.
192. Smedslund G, Kotar AM, Uhlig T. Sarcoidosis with musculoskeletal manifestations: systematic review of non-pharmacological and pharmacological treatments. Rheumatol Int. 2022;42:2109-24.
193. Sharma R, Guleria R, Mohan A. Treatment of pulmonary sarcoidosis with hydroxycholoroquine: result of a pilot study from Indi. Chest. 2003;124:109S.
194. Ben Hassine I, Rein C, Comarmond C, et al. Osseous sarcoidosis: A multicenter retrospective case-control study of 48 patients. Joint Bone Spine. 2019;86:789-93.
195. Sharma OP. Effectiveness of chloroquine and hydroxychloroquine in treating selected patients with sarcoidosis with neurological involvement. Arch Neurol. 1998;55:1248-54.
196. Lee W, Ruijgrok L, Boxma-de Klerk B, et al. Efficacy of hydroxychloroquine in hand osteoarthritis: a randomized, double-blind, placebo-controlled trial. Arthritis Care Res. 2018;70:1320-5.
197. Kingsbury SR, Tharmanathan P, Keding A, et al. Hydroxychloroquine effectiveness in reducing symptoms of hand osteoarthritis: a randomized trial. Ann Intern Med. 2018;168:385-95.
198. Wright NA, Mazori DR, Patel M, Merola JF, Femia AN, Vleugels RA. Epidemiology and treatment of eosinophilic fasciitis: an analysis of 63 patients from 3 tertiary care centers. JAMA Dermatol. 2016;152:97-9.
199. Woo TY, Callen JP, Voorhees JJ, Bickers DR, Hanno R, Hawkins C. Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine. J Am Acad Dermatol. 1984;10:592-600.
200. Zhang QC, Liu MY, Chen ZX, Chen YT, Lin CS, Xu Q. Case report: treatment of anti-MDA5-positive amyopathic dermatomyositis accompanied by a rapidly progressive interstitial lung diseases with methylprednisolone pulse therapy combined with cyclosporine A and hydroxychloroquine. Front Med. 2020;7:610554.
201. Olson NY, Lindsley CB. Adjunctive use of hydroxychloroquine in childhood dermatomyositis. J Rheumatol. 1989;16:1545-7.
202. Lin YC, Huang HH, Nong BR, et al. Pediatric Kikuchi-Fujimoto disease: a clinicopathologic study and the therapeutic effects of hydroxychloroquine. J Microbiol Immunol Infect. 2019;52:395-401.
203. Hyun M, So IT, Kim HA, Jung H, Ryu SY. Recurrent Kikuchi's disease treated by hydroxychloroquine. Infect Chemother. 2016;48:127-31.
204. Sun L, Gong YR, Chen Q, et al. Application and safety of hydroxychloroquine in chronic disease among children. Zhonghua Er Ke Za Zhi. 2021;59:107-12.
205. Nogueira IA, Cordeiro RA, Henn GAL, Oliveira JL. Hydroxychloroquine for the management of chronic chikungunya arthritis. Rev Inst Med Trop Sao Paulo. 2023;65:e26.
206. Mohammadpour F, Kargar M, Hadjibabaie M. The role of hydroxychloroquine as a steroid-sparing agent in the treatment of immune thrombocytopenia: a review of the literature. J Res Pharm Pract. 2018;7:4-12.
207. Bockow B, Kaplan TB. Refractory immune thrombocytopenia successfully treated with high-dose vitamin D supplementation and hydroxychloroquine: two case reports. J Med Case Rep. 2013;7:91.
208. Zhang J, Lu X, Feng J, Li H, Wang S. Effects of hydroxychloroquine on proteinuria in IgA nephropathy: a systematic review and meta-analysis. Biomed Res Int. 2021;2021:9171715.
209. Liu LJ, Yang YZ, Shi SF, et al. Effects of hydroxychloroquine on proteinuria in IgA nephropathy: a randomized controlled trial. Am J Kidney Dis. 2019;74:15-22.
210. Si FL, Tang C, Lv JC, et al. Comparison between hydroxychloroquine and systemic corticosteroids in IgA nephropathy: a two-year follow-up study. BMC Nephrol. 2023;24:175.
211. WHO guidelines for malaria. Available from https://www.who.int/publications/i/item/guidelines-for-malaria [Last accessed on 27 Feb 2024].
212. Horby P, Mafham M, Linsell L, et al. RECOVERY Collaborative Group. Effect of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020;383:2030-40.
213. Arabi YM, Gordon AC, Derde LPG, et al. REMAP-CAP Investigators. Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. Intensive Care Med. 2021;47:867-86.
214. Sivapalan P, Ulrik CS, Lapperre TS, et al. ProPAC-COVID writing group on behalf of the ProPAC-COVID Study Group. Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19: a randomised double-blinded placebo-controlled trial. Eur Respir J. 2022;59:2100752.
215. Pan H, Peto R, Henao-Restrepo AM, et al. WHO Solidarity Trial Consortium. Repurposed antiviral drugs for Covid-19 - interim WHO solidarity trial results. N Engl J Med. 2021;384:497-511.
216. Pradelle A, Mainbourg S, Provencher S, Massy E, Grenet G, Lega JC. Deaths induced by compassionate use of hydroxychloroquine during the first COVID-19 wave: an estimate. Biomed Pharmacother. 2024;171:116055.
217. Diagnosis and management of Q fever - United States, 2013: recommendations from CDC and the Q fever working group. Available from: https:// www.cdc.gov/mmwr/preview/mmwrhtml/rr6203a1.htm [Last accessed on 27 Feb 2024].
218. Coxiella burnetii infection. BMJ Best Practice Available from: https://bestpractice.bmj.com/topics/en-gb/1139 [Last accessed on 27 Feb 2024].
219. Whipple’s disease. BMJ Best Practice Available from: https://bestpractice.bmj.com/topics/en-gb/467 [Last accessed on 27 Feb 2024].
220. Wang X, Long X, Jia S, et al. In vitro and in vivo synergistic effects of hydroxychloroquine and itraconazole on Cryptococcus neoformans. Folia Microbiol. 2023;68:595-605.
221. Luo W, Che D, Lu H, Jiang Y. New perspectives from misdiagnosis: a case of primary cutaneous cryptococcosis treated with hydroxychloroquine sulfate successfully. Mycopathologia. 2020;185:595-6.
222. Rolain JM, Colson P, Raoult D. Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. Int J Antimicrob Agents. 2007;30:297-308.
223. Dias-Melicio LA, Moreira AP, Calvi SA, Soares AM. Chloroquine inhibits paracoccidioides brasiliensis survival within human monocytes by limiting the availability of intracellular iron. Microbiol Immunol. 2006;50:307-14.
224. Naghipour S, Ghodousi M, Rahsepar S, Elyasi S. Repurposing of well-known medications as antivirals: hydroxychloroquine and chloroquine - from HIV-1 infection to COVID-19. Expert Rev Anti Infect Ther. 2020;18:1119-33.
225. Shiryaev SA, Mesci P, Pinto A, et al. Repurposing of the anti-malaria drug chloroquine for Zika virus treatment and prophylaxis. Sci Rep. 2017;7:15771.
226. Hamilton BK. Updates in chronic graft-versus-host disease. Hematol Am Soc Hematol Educ Program. 2021;2021:648-54.
227. Gilman AL, Chan KW, Mogul A, et al. Hydroxychloroquine for the treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2000;6:327-34.
228. Khoury H, Trinkaus K, Zhang MJ, et al. Hydroxychloroquine for the prevention of acute graft-versus-host disease after unrelated donor transplantation. Biol Blood Marrow Transplant. 2003;9:714-21.
229. Fong T, Trinkaus K, Adkins D, et al. A randomized double-blind trial of hydroxychloroquine for the prevention of chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2007;13:1201-6.
230. Gilman AL, Schultz KR, Goldman FD, et al. Randomized trial of hydroxychloroquine for newly diagnosed chronic graft-versus-host disease in children: a children's oncology group study. Biol Blood Marrow Transplant. 2012;18:84-91.
231. Lagneaux L, Delforge A, Dejeneffe M, Massy M, Bernier M, Bron D. Hydroxychloroquine-induced apoptosis of chronic lymphocytic leukemia involves activation of caspase-3 and modulation of Bcl-2/bax/ratio. Leuk Lymphoma. 2002;43:1087-95.
232. Mansilla E, Marin GH, Nuñez L, et al. The lysosomotropic agent, hydroxychloroquine, delivered in a biodegradable nanoparticle system, overcomes drug resistance of B-chronic lymphocytic leukemia cells in vitro. Cancer Biother Radiopharm. 2010;25:97-103.
233. Jiang PD, Zhao YL, Shi W, et al. Cell growth inhibition, G2/M cell cycle arrest, and apoptosis induced by chloroquine in human breast cancer cell line Bcap-37. Cell Physiol Biochem. 2008;22:431-40.
234. Rahim R, Strobl JS. Hydroxychloroquine, chloroquine, and all-trans retinoic acid regulate growth, survival, and histone acetylation in breast cancer cells. Anticancer Drugs. 2009;20:736-45.
236. Cainelli T, Di Padova C, Marchesi L, et al. Hydroxychloroquine versus phlebotomy in the treatment of porphyria cutanea tarda. Br J Dermatol. 1983;108:593-600.
237. Marchesi L, Di Padova C, Cainelli T, et al. A comparative trial of desferrioxamine and hydroxychloroquine for treatment of porphyria cutanea tarda in alcoholic patients. Photodermatology. 1984;1:286-92.
238. Singal AK, Kormos-Hallberg C, Lee C, et al. Low-dose hydroxychloroquine is as effective as phlebotomy in treatment of patients with porphyria cutanea tarda. Clin Gastroenterol Hepatol. 2012;10:1402-9.
239. Pareek A, Khopkar U, Sacchidanand S, Chandurkar N, Naik GS. Comparative study of efficacy and safety of hydroxychloroquine and chloroquine in polymorphic light eruption: a randomized, double-blind, multicentric study. Indian J Dermatol Venereol Leprol. 2008;74:18-22.
240. Hrin ML, Feldman SR, Huang WW. Hydroxychloroquine for generalized granuloma annulare: 35% response rate in a retrospective case series of 26 patients. J Am Acad Dermatol. 2022;87:144-7.
241. Eisen D. Hydroxychloroquine sulfate (Plaquenil) improves oral lichen planus: an open trial. J Am Acad Dermatol. 1993;28:609-12.
242. Husein-ElAhmed H, Gieler U, Steinhoff M. Lichen planus: a comprehensive evidence-based analysis of medical treatment. J Eur Acad Dermatol Venereol. 2019;33:1847-62.
243. Stoopler ET, Kulkarni R, Alawi F, Sollecito TP. Novel combination therapy of hydroxychloroquine and topical tacrolimus for chronic ulcerative stomatitis. Int J Dermatol. 2021;60:e162-3.
244. Brant EG, Akilov O. Hydroxychloroquine for the treatment of hidradenitis suppurativa. JAAD Case Rep. 2023;37:64-7.
245. Khan N, Epstein TG, DuBuske I, Strobel M, Bernstein DI. Effectiveness of hydroxychloroquine and omalizumab in chronic spontaneous urticaria: a real-world study. J Allergy Clin Immunol Pract. 2022;10:3300-5.
246. Reeves GE, Boyle MJ, Bonfield J, Dobson P, Loewenthal M. Impact of hydroxychloroquine therapy on chronic urticaria: chronic autoimmune urticaria study and evaluation. Intern Med J. 2004;34:182-6.
247. Koch MW, Kaur S, Sage K, et al. Hydroxychloroquine for primary progressive multiple sclerosis. Ann Neurol. 2021;90:940-8.
248. Sun L, Kuang XY, Zhang J, Huang WY. Hydroxychloroquine ameliorates hematuria in children with X-linked alport syndrome: retrospective case series study. Pharmgenomics Pers Med. 2023;16:145-51.
249. Plantone D, Koudriavtseva T. Current and future use of chloroquine and hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases: a mini-review. Clin Drug Investig. 2018;38:653-71.
250. Guennec P, Dromer C, Sixou L, Marc V, Coustals P, Fournié B. Treatment of horton disease. value of synthetic antimalarials. apropos of a retrospective study of 36 patients. Rev Rhum Ed Fr. 1994;61:485-90.
251. Hydroxychloroquine in giant cell arteritis. Available from: https://classic.clinicaltrials.gov/ct2/show/record/NCT00430807 [Last accessed on 27 Feb 2024].
252. Rongyi C, Zongfei J, Jiang L, et al. Effect of hydroxychloroquine on angiographic progression in routine treatment of takayasu arteritis. Mod Rheumatol. 2021;31:1135-41.
253. Casian A, Sangle S, D'cruz D. AB0531 the role of hydroxychloroquine in ANCA positive and negative vasculitis. Ann Rheum Dis. 2016;75:1086-7.
254. Papachristodoulou E, Kakoullis L, Tiniakou E, Parperis K. Therapeutic options for cutaneous polyarteritis nodosa: a systematic review. Rheumatology. 2021;60:4039-47.
255. Panda PK, Sharawat IK, Natarajan V, Bhakat R, Panda P, Dawman L. COVID-19 treatment in children: a systematic review and meta-analysis. J Family Med Prim Care. 2021;10:3292-302.
256. Kolkhir P, Grakhova M, Bonnekoh H, Krause K, Maurer M. Treatment of urticarial vasculitis: a systematic review. J Allergy Clin Immunol. 2019;143:458-66.
257. Bostan E, Akdogan N, Gokoz O, Dogan S. Rapid response to combination of hydroxychloroquine and prednisolone in a patient with refractory hypocomplementemic urticarial vasculitis. Dermatol Ther. 2020;33:e14531.
258. Lopez LR, Davis KC, Kohler PF, Schocket AL. The hypocomplementemic urticarial-vasculitis syndrome: therapeutic response to hydroxychloroquine. J Allergy Clin Immunol. 1984;73:600-3.
259. Batioğlu F, Taner P, Aydintuğ OT, Heper AO, Ozmert E. Recurrent optic disc and retinal vasculitis in a patient with drug-induced urticarial vasculitis. Cutan Ocul Toxicol. 2006;25:281-5.
260. Farkas H, Szongoth M, Bély M, et al. Angiooedema due to acquired deficiency of C1-esterase inhibitor associated with leucocytoclastic vasculitis. Acta Derm Venereol. 2001;81:298-300.
261. Jachiet M, Flageul B, Deroux A, et al. French Vasculitis Study Group. The clinical spectrum and therapeutic management of hypocomplementemic urticarial vasculitis: data from a French nationwide study of fifty-seven patients. Arthritis Rheumatol. 2015;67:527-34.
262. Basnet A, Cholankeril MR. Hemophagocytic lymphohistiocytosis in a patient with goodpasture's syndrome: a rare clinical association. Am J Case Rep. 2014;15:431-6.
